Evidence map›Paper›PMID 27246584›Full record

ArticleEuropean respiratory review : an official journal of the European Respiratory Society2016

Why we should care about ultra-rare disease.

Sergio Harari

Abstract readEditorial
In one paragraph

Article in European respiratory review : an official journal of the European Respiratory Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Rare diseases: What rheumatologists need to know?Advances in rheumatology (London, England) · 2024
    Review
  6. Review
  7. Article
  8. Article
  9. Literature Review on Health Emigration in Rare Diseases-A Machine Learning Perspective.International journal of environmental research and public health · 2023
    Review
  10. Article
  11. Article
  12. Review
  13. Some take-home messages from the 9th International Meeting on Pulmonary Rare Diseases and Orphan Drugs.European respiratory review : an official journal of the European Respiratory Society · 2021
    Article
  14. Next-generation strategies for gene-targeted therapies of central nervous system disorders: A workshop summary.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Ultra-rare disease: an European perspective.European respiratory review : an official journal of the European Respiratory Society · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Sergio HarariU.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria-Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare, Ospedale San Giuseppe-MultiMedica IRCCS, Milan, Italy sharari@hotmail.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug DiscoveryEuropeGovernment RegulationHealth PolicyHealth Services AccessibilityHumansLung DiseasesOrphan Drug ProductionRare Diseases

Identifiers

PMID27246584
PMCPMC9487247

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.